Do you want to read an article? Please log in or register.
Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies
Psoriatic Arthritis
Related content
Psoriatic ArthritisRheumatoid Arthritis
Secukinumab Efficacy on Enthesitis in Patients with Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase 3 Studies
J Rheumatol
Schett G, Baraliakos X, Van den Bosch F, Deodhar A, Østergaard M, Das Gupta A, Mpofu S, Fox T, Winseck A, Porter B, Shete A, Gensler LS
doi: 10.3899/jrheum.201111
RECOMMENDED
Psoriatic Arthritis
Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis
doi: 10.1186/s13075-019-1831-0.
Psoriasis
Resolution of Enthesitis by Guselkumab and Relationships to Disease Burden: 1-Year Results of Two Phase-3 Psoriatic Arthritis Studies
Rheumatology (Oxford)
McGonagle D, McInnes IB, Deodhar A, Schett G, Shawi M, Kafka S, Karyekar CS, Kollmeier AP, Hsia EC, Xu XL, Sheng S, Agarwal P, Zhou B, Ritchlin CT, Rahman P, Mease PJ
doi: 10.1093/rheumatology/keab285
Psoriatic Arthritis
Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients
J Rheumatol.
Orbai AM, McInnes IB, Coates LC, Husni ME, Gladman DD, Gossec L, Pricop L, Chambenoit O, Meng X, Mease PJ
doi: 10.3899/jrheum.190507.
COMMENTED
Psoriatic Arthritis
Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5
★ 3
Recommended and commented by
Dr Heino Prillwitz, Faculty Member
Rheumatology (Oxford).
van der Heijde D, Mease PJ, Landewé RBM, Rahman P, Tahir H, Singhal A, Boettcher E, Navarra S, Zhu X, Ligozio G, Readie A, Mpofu S, Pricop L
doi: 10.1093/rheumatology/kez420.
Further Publications Rheumatology
Long-term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through 2 Years: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis
Arthritis Rheumatol
McInnes IB, Rahman P, Gottlieb AB, Hsia EC, Kollmeier AP, Xu XL, Jiang Y, Sheng S, Shawi M, Chakravarty SD, van der Heijde D, Mease PJ
doi: 10.1002/art.42010
Psoriatic Arthritis
Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
Rheumatol Ther.
Nash P, Coates LC, Kivitz AJ, Mease PJ, Gladman DD, Covarrubias-Cobos JA, FitzGerald O, Fleishaker D, Wang C, Wu J, Hsu MA, Menon S, Fallon L, Romero AB, Kanik KS
doi: 10.1007/s40744-020-00209-4.
Psoriatic Arthritis
Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies
J Eur Acad Dermatol Venereol.
Merola JF, Papp KA, Nash P, Gratacós J, Boehncke WH, Thaçi D, Graham D, Hsu MA, Wang C, Wu J, Young P
doi: 10.1111/jdv.16433.
Psoriatic Arthritis
Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis
Arthritis Res Ther.
Kavanaugh A, Gladman DD, Edwards CJ, Schett G, Guerette B, Delev N, Teng L, Paris M, Mease PJ
doi: 10.1186/s13075-019-1901-3.